Literature DB >> 22570084

Disparities in head and neck cancer: assessing delay in treatment initiation.

Urjeet A Patel1, Tara E Brennan.   

Abstract

OBJECTIVES/HYPOTHESIS: Disparities in outcome for head and neck cancer (HNC) treatment are related to diverse factors including tumor stage, socioeconomic status, and treatment compliance. Latency to initiation of therapy may contribute to worse outcomes for underserved populations. The objectives of this study were to measure the interval from diagnosis of HNC to initiation of cancer treatment (DTI) and to identify factors that prolong DTI. STUDY
DESIGN: Retrospective study.
METHODS: We identified 150 consecutive patients treated for squamous cell HNC at a tertiary-care public hospital between 2005 and 2007. Outcome measures used were 1) interval between cancer diagnosis and treatment initiation and 2) factors that predict prolonged DTI.
RESULTS: We included 100 patients in the analysis. Median time to perform biopsy was 8 days; time to obtain final diagnosis was 14 days; time to complete staging scans was 18 days; time to discuss treatment plan was 23 days; time to initiation of therapy was 56 days. Median DTI was 48 days. DTI was prolonged for patients receiving primary radiotherapy compared to surgical therapy: 57 versus 30 days (P < .001). Early stage tumors had shorter DTI than late-stage tumors: 38 versus 57 days (P = .02). Presenting with outside biopsy demonstrating HNC also reduced DTI (P = .03). Obtaining a computed tomography scan in the emergency department was not found to significantly affect DTI.
CONCLUSIONS: DTI was found to be prolonged among HNC patients in this study when compared to previously published treatment intervals. Advanced stage of tumor, primary radiotherapy, and need for biopsy prolonged DTI. Future studies should better identify causes of delay and reduce latency for patients at highest risk for delay.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22570084     DOI: 10.1002/lary.23357

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  18 in total

1.  Insurance status as a predictor of mortality in patients undergoing head and neck cancer surgery.

Authors:  Matthew L Rohlfing; Ashley C Mays; Scott Isom; Joshua D Waltonen
Journal:  Laryngoscope       Date:  2017-06-22       Impact factor: 3.325

2.  The effect of time between diagnosis and initiation of treatment on outcomes in patients with head and neck squamous cell carcinoma.

Authors:  Luke H DeGraaff; Alexis J Platek; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni Abraham Kuriakose; Wesley L Hicks; Mary E Platek; Anurag K Singh
Journal:  Oral Oncol       Date:  2019-07-30       Impact factor: 5.337

3.  Comparison of Clinical Outcomes Following Head and Neck Surgery Among Patients Who Contract to Abstain From Alcohol vs Patients Who Abuse Alcohol.

Authors:  Azeem S Kaka; Songzhu Zhao; Enver Ozer; Amit Agrawal; Stephen Kang; James Rocco; Ricardo Carrau; Theodoros Teknos; John D Clapp; Harrison Weed; Matthew O Old
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-12-01       Impact factor: 6.223

4.  Investigating Patient and Physician Delays in the Diagnosis of Head and Neck Cancers: a Canadian Perspective.

Authors:  Jonghun John Lee; Chris Dhepnorrarat; Joyce Nyhof-Young; Ian Witterick
Journal:  J Cancer Educ       Date:  2016-03       Impact factor: 2.037

5.  Population analysis of socioeconomic status and otolaryngologist distribution on head and neck cancer outcomes.

Authors:  Nitin A Pagedar; Andrew B Davis; Steven M Sperry; Mary E Charlton; Charles F Lynch
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

6.  Travel distance is associated with stage at presentation and laryngectomy rates among patients with laryngeal cancer.

Authors:  Elliot Morse; Shivangi Lohia; Laura M Dooley; Piyush Gupta; Benjamin R Roman
Journal:  J Surg Oncol       Date:  2021-08-14       Impact factor: 2.885

7.  Delay in diagnosis of patients with head-and-neck cancer in Canada: impact of patient and provider delay.

Authors:  S Kassirian; A Dzioba; S Hamel; K Patel; A Sahovaler; D A Palma; N Read; V Venkatesan; A C Nichols; J Yoo; K Fung; A Mendez; S D MacNeil
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

8.  What are the real waiting times for therapeutic management of head and neck cancer: a study in the general population in the north-west of France.

Authors:  Anne-Valerie Guizard; Olivier Dejardin; Ludivine Launay; Simona Bara; Bénédicte Lapôtre-Ledoux; Emmanuel Babin; Guy Launoy; Karine Ligier
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-27       Impact factor: 2.503

9.  Identifying the Factors Causing Delayed Presentation of Cancer Patients to a Government Medical College of Central India.

Authors:  Vivek Tiwari; Veenita Yogi; Hameed Uzzafar Ghori; Om Prakash Singh; Karan Peepre; Suresh Yadav; Chaitlal Mohare
Journal:  J Clin Diagn Res       Date:  2015-09-01

10.  Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).

Authors:  Katrin Oertel; Karin Spiegel; Harald Schmalenberg; Andreas Dietz; Georg Maschmeyer; Thomas Kuhnt; Holger Sudhoff; Thomas G Wendt; Orlando Guntinas-Lichius
Journal:  BMC Cancer       Date:  2012-10-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.